Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Mont...(Three Months Ended Nine Months End...),Health

Date:11/5/2009

Three Months Ended Nine Months Ended September 30, September 30, ------------------ ----------------- 2009 2008 2009 2008 ---- ---- ---- ---- Revenues $50,807 $32,087 $135,294 $82,210 Cost of revenues 18,402 12,282 50,603 32,663 ------ ------ ------ ------ Gross profit 32,405 19,805 84,691 49,547 Operating expenses: Sales and marketing 8,217 5,098 22,538 14,529 General and administrative 7,287 5,786 21,168 16,091 Research and development 522 333 1,049 1,003 --- --- ----- ----- Total operating expenses 16,026 11,217 44,755 31,623 ------ ------ ------ ------ Income from operations 16,379 8,588 39,936 17,924 Interest and other income 334 650 1,268 2,302 --- --- ----- ----- Income before income taxes 16,713 9,238 41,204 20,226 Income tax expense (benefit) 7,251 (6,190) 17,926 (5,780) ----- ------- ------ ------- Net income $9,462 $15,428 $23,278 $26,006 ------ ------- ------- ------- Net income per share: Basic $0.55 $0.93 $1.38 $1.59 ----- ----- ----- -----
'/>"/>

SOURCE Genoptix, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors